GROWTH-HORMONE TREATMENT IMPROVES SERUM-LIPIDS AND LIPOPROTEINS IN ADULTS WITH GROWTH-HORMONE DEFICIENCY

被引：224

作者：

CUNEO, RC

SALOMON, F

WATTS, GF

HESP, R

SONKSEN, PH

机构：

[1] UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,DIV ENDOCRINOL & CHEM PATHOL,LONDON SE1 7EH,ENGLAND

[2] NORTHWICK PK HOSP & CLIN RES CTR,MRC,DIV RADIOISOTOPES,HARROW HA1 3UJ,MIDDX,ENGLAND

来源：

METABOLISM-CLINICAL AND EXPERIMENTAL | 1993年 / 42卷 / 12期

关键词：

D O I：

10.1016/0026-0495(93)90145-E

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The effects of 6 months' treatment with recombinant human growth hormone (rhGH) on serum lipids and lipoproteins were assessed in 24 adult patients with GH deficiency in a double-blind, placebo-controlled trial. Compared with age-, weight-, and sex-matched controls, the patients had significantly higher serum concentrations of total cholesterol (P = .002), low-density lipoprotein (LDL) cholesterol (P < .001), apolipoprotein B ([apoB] P = .011), and triglyceride (P = .017), and lower concentrations of high-density lipoprotein (HDL) cholesterol (P < .001). The prevalence of elevated serum cholesterol, triglyceride, LDL cholesterol, and apo B levels was 39%, 26%, 39%, and 25%, respectively; 75% of patients had decreased concentrations of HDL cholesterol. Treatment with rhGH (0.07 U/kg daily) resulted in decreases in total cholesterol level (5.8 ± 0.3 to 5.1 ± 0.3 mmol · L-1 over 6 months; P = .01 compared with placebo), LDL cholesterol level (4.22 ± 0.25 to 3.19 ± 0.23 mmol · L-1; P = .0003), LDL:HDL cholesterol ratio (5.57 ± 0.47 to 3.29 ± 0.33; P = .03), apo B level (1.07 ± 0.06 to 0.84 ± 0.07 g · L-1; P = .003), and apo B: A-1 ratio (0.73 ± 0.05 to 0.69 ± 0.05; P = .01). HDL cholesterol and apo A-1 levels did not change following rhGH treatment. The changes in lipid and lipoprotein levels were not significantly related to changes in insulin, thyroid hormones, insulin-like growth factor-1 (IGF-1), or indices of adiposity. The data suggest that (1) adults with GH deficiency may be at increased risk of cardiovascular (CVS) disease due to hyperlipidemia, and (2) long-term treatment with rhGH improves lipid and lipoprotein profiles. Alterations in CVS mortality following long-term rhGH treatment remain to be assessed. © 1993.

引用

页码：1519 / 1523

页数：5

共 32 条

[1]

Havel, Lowering cholesterol. 1988. Rationale, mechanisms, and means, J Clin Invest, 81, pp. 1653-1660, (1988)

[2]

Rosen, Bengtsson, Premature mortality due to cardiovascular disease in hypopituitarism, Lancet, 336, pp. 285-288, (1990)

[3]

Asayama, Amemiya, Kusano, Et al., Growth-hormone-induced changes in postheparin plasma lipoprotein lipase and hepatic triglyceride lipase activities, Metabolism, 33, pp. 129-131, (1984)

[4]

Blackett, Weech, McConathy, Et al., Growth hormone in the regulation of hyperlipidemia, Metabolism, 31, pp. 117-120, (1982)

[5]

LaFranchi, Hanna, Illingworth, Effect of growth hormone replacement on the development of hypothyroidism and hyperlipidemia, J Pediatr, 106, pp. 588-593, (1985)

[6]

Winter, Thompson, Green, Serum cholesterol and triglycerides in children with growth hormone deficiency, Metabolism, 28, pp. 1244-1249, (1979)

[7]

Libber, Plotnick, Johanson, Et al., Long-term follow-up of hypopituitary patients treated with human growth hormone, Medicine, 69, pp. 46-55, (1990)

[8]

Merimee, Hollander, Fineberg, Studies of hyperlipidemia in the HGH-deficient state, Metabolism, 21, pp. 1053-1061, (1972)

[9]

Merimee, Fineberg, Hollander, Vascular disease in the chronic HGH-deficient state, Diabetes, 22, pp. 813-819, (1973)

[10]

Salomon, Cuneo, Hesp, Et al., The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency, N Engl J Med, 321, pp. 1797-1803, (1989)

← 1 2 3 4 →